VERNON, France, Jan. 25,
2023 /PRNewswire/ -- Sysnav Healthcare and Roche
enter a partnership to facilitate development of industry standard
outcome measurements in diseases associated with movement
impairments, as well as designing the next generation of
wearable technology based on Sysnav's unique technology.
Patients living with a neuromuscular disorder often suffer from
movement impairments that fundamentally impact their daily life.
Reliable, objective measurements of a patient's change in motor
function can help doctors prescribe the most appropriate therapy
and support research aimed to develop new medicines which improve
lives. Sysnav Healthcare has developed medical grade wearables
based on magneto-inertial technology for 3D movement
reconstruction. This enables precise movement tracking without GPS,
thus protecting patient privacy while enabling indoor monitoring.
Sysnav has already secured the first-ever qualification of a
digital endpoint (SV95c) with the European Medicines Agency for
Duchenne's Muscular Dystrophy, having worked closely with academic
collaborators, patients associations and Roche.
Sysnav Healthcare and Roche have expanded their collaboration
across multiple programs to develop meaningful digital endpoints
that will monitor disease progression, support clinical trials and
serve as regulatory approved standards of outcome measurement. The
partnership will also develop the next generation wearable
technology to further promote personalised healthcare. "Sysnav's
technology offers the opportunity to measure functional disease
progression to a regulatory standard across a range of diseases.
This has the potential to improve the way patients are involved in
clinical studies, the ability to determine potential treatment
benefits, and enrich our understanding of disease pathophysiology,"
says James Sabry, Global Head of
Roche Pharma Partnering.
"When high precision technology meets clinical expertise, it
is a game-changing combination to accelerate medical progress.
Bringing together Sysnav's digital health technology and Roche's
expertise in neuroscience drug development and personalised
healthcare will enable us to have a truly meaningful impact on
patients with motor impairments. By establishing a new set
of industry standards for the evaluation of motor impairments, we
can unlock innovation for the benefit of all patients," says
Damien Eggenspieler, Sysnav Healthcare Program Director.
About Sysnav Healthcare
Sysnav Healthcare is a leading business unit of Sysnav, a
fast-growing French independent tech company. Since the start of
its activities, Sysnav Healthcare aims to unlock the potential of
real-world data in the medical field by adapting extremely precise
motion-capture solutions to the needs of healthcare professionals
and patients. The company has already developed two wearable
devices: ActiMyo® & Syde® and is the first-ever to qualify a
digital endpoint (SV95c) with EMA. Sysnav Healthcare, as the
pioneer and leader for movement evaluation in clinical trials, is
now building the next generation of digital health technologies so
that patients benefit earlier and more reliably from life-changing
For more information, visit: www.healthcare.sysnav.com
SOURCE Sysnav Healthcare